Exploring FDA-Approved Frontiers: Insights into Natural and Engineered Peptide Analogues in the GLP-1, GIP, GHRH, CCK, ACTH, and α-MSH Realms.

This review paper examines the landscape of FDA-approved peptide therapeutics, tracing the field's evolution from the discovery of insulin in 1921 to approximately 100 subsequently authorized peptide drugs. The author focuses on six key peptide classes: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) analogues for diabetes management, growth-hormone-releasing hormone (GHRH) analogues, cholecystokinin (CCK) analogues, adrenocorticotropic hormone (ACTH) analogues, and α-melanocyte-stimulating hormone (α-MSH) analogues. For each class, the review describes the native peptide's biological structure and mechanism of action, the medicinal chemistry strategies used to engineer synthetic analogues (such as modifications that extend half-life and reduce dosing frequency), the developmental and regulatory journey toward FDA approval, and known adverse effects. The paper highlights how targeted chemical modifications—including structural stabilization techniques—have improved the therapeutic utility of naturally derived peptides beyond their endogenous counterparts. Limitations include those inherent to any narrative review: no systematic search methodology or meta-analytic statistics are reported, and no original clinical or experimental data are generated. The work serves primarily as an educational synthesis of existing literature.

Why this grade: This is a narrative review synthesizing existing literature on FDA-approved peptide analogues; it generates no original clinical, animal, or in-vitro data of its own, making it classified as a review-level evidence source.